Equity Overview
Price & Market Data
Price: $0.318
Daily Change: -$0.0078 / 2.45%
Daily Range: $0.302 - $0.326
Market Cap: $13,194,337
Daily Volume: 286,765
Performance Metrics
1 Week: 0.68%
1 Month: -8.39%
3 Months: -8.64%
6 Months: -38.79%
1 Year: -85.00%
YTD: -89.14%
Company Details
Employees: 52
Sector: Health technology
Industry: Biotechnology
Country:
Details
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.